132 related articles for article (PubMed ID: 12033506)
1. Effects of 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] and its analogues (EB1089 and analog V) on canine adenocarcinoma (CAC-8) in nude mice.
Kunakornsawat S; Rosol TJ; Capen CC; Reddy GS; Binderup L; Inpanbutr N
Biol Pharm Bull; 2002 May; 25(5):642-7. PubMed ID: 12033506
[TBL] [Abstract][Full Text] [Related]
2. A vitamin D analogue (EB1089) inhibits parathyroid hormone-related peptide production and prevents the development of malignancy-associated hypercalcemia in vivo.
Haq M; Kremer R; Goltzman D; Rabbani SA
J Clin Invest; 1993 Jun; 91(6):2416-22. PubMed ID: 8514854
[TBL] [Abstract][Full Text] [Related]
3. Effects of 1,25(OH)2D3, EB1089, and analog V on PTHrP production, PTHrP mRNA expression and cell growth in SCC 2/88.
Kunakornsawat S; Rosol TJ; Capen CC; Middleton RP; Hannah SS; Inpanbutr N
Anticancer Res; 2001; 21(5):3355-63. PubMed ID: 11848494
[TBL] [Abstract][Full Text] [Related]
4. Growth suppression of ovarian cancer xenografts in nude mice by vitamin D analogue EB1089.
Zhang X; Jiang F; Li P; Li C; Ma Q; Nicosia SV; Bai W
Clin Cancer Res; 2005 Jan; 11(1):323-8. PubMed ID: 15671562
[TBL] [Abstract][Full Text] [Related]
5. Dependence of humoral hypercalcemia of malignancy on parathyroid hormone-related protein expression in the canine anal sac apocrine gland adenocarcinoma (CAC-8) nude mouse model.
Gröne A; Weckmann MT; Blomme EA; Capen CC; Rosol TJ
Vet Pathol; 1998 Sep; 35(5):344-51. PubMed ID: 9754539
[TBL] [Abstract][Full Text] [Related]
6. Apoptotic regression of MCF-7 xenografts in nude mice treated with the vitamin D3 analog, EB1089.
VanWeelden K; Flanagan L; Binderup L; Tenniswood M; Welsh J
Endocrinology; 1998 Apr; 139(4):2102-10. PubMed ID: 9528999
[TBL] [Abstract][Full Text] [Related]
7. Vitamin D analogs: new therapeutic agents for the treatment of squamous cancer and its associated hypercalcemia.
Yu J; Papavasiliou V; Rhim J; Goltzman D; Kremer R
Anticancer Drugs; 1995 Feb; 6(1):101-8. PubMed ID: 7756673
[TBL] [Abstract][Full Text] [Related]
8. Ultrastructural and histomorphometric evaluations of gallium nitrate on bone in nude mice bearing a canine adenocarcinoma (CAC-8) model of humoral hypercalcemia of malignancy.
Okada H; Merryman JI; Capen CC; Rosol TJ
Vet Pathol; 1995 Jan; 32(1):36-42. PubMed ID: 7725596
[TBL] [Abstract][Full Text] [Related]
9. Effects of gallium nitrate in nude mice bearing a canine adenocarcinoma (CAC-8) model of humoral hypercalcemia of malignancy.
Merryman JI; Capen CC; Rosol TJ
J Bone Miner Res; 1994 May; 9(5):725-32. PubMed ID: 8053402
[TBL] [Abstract][Full Text] [Related]
10. 1,25-dihydroxyvitamin D3 as well as its analogue OCT lower blood calcium through inhibition of bone resorption in hypercalcemic rats with continuous parathyroid hormone-related peptide infusion.
Endo K; Katsumata K; Hirata M; Masaki T; Kubodera N; Nakamura T; Ikeda K; Ogata E
J Bone Miner Res; 2000 Jan; 15(1):175-81. PubMed ID: 10646127
[TBL] [Abstract][Full Text] [Related]
11. Bone turnover in rats treated with 1,25-dihydroxyvitamin D3, 25-hydroxyvitamin D3 or 24,25-dihydroxyvitamin D3.
Mortensen BM; Gautvik KM; Gordeladze JO
Biosci Rep; 1993 Feb; 13(1):27-39. PubMed ID: 8392394
[TBL] [Abstract][Full Text] [Related]
12. Selective biological response by target organs (intestine, kidney, and bone) to 1,25-dihydroxyvitamin D3 and two analogues.
Norman AW; Sergeev IN; Bishop JE; Okamura WH
Cancer Res; 1993 Sep; 53(17):3935-42. PubMed ID: 8395333
[TBL] [Abstract][Full Text] [Related]
13. Reversal of hypercalcemia with the vitamin D analogue EB1089 in a human model of squamous cancer.
El Abdaimi K; Papavasiliou V; Rabbani SA; Rhim JS; Goltzman D; Kremer R
Cancer Res; 1999 Jul; 59(14):3325-8. PubMed ID: 10416587
[TBL] [Abstract][Full Text] [Related]
14. Antiestrogens inhibit in vitro bone resorption stimulated by 1,25-dihydroxyvitamin D3 and the vitamin D3 analogs EB1089 and KH1060.
Vink-van Wijngaarden T; Birkenhäger JC; Kleinekoort WM; van den Bemd GJ; Pols HA; van Leeuwen JP
Endocrinology; 1995 Feb; 136(2):812-5. PubMed ID: 7835315
[TBL] [Abstract][Full Text] [Related]
15. Differential effects of 1,25-dihydroxyvitamin D3-analogs on osteoblast-like cells and on in vitro bone resorption.
van den Bemd GJ; Pols HA; Birkenhäger JC; Kleinekoort WM; van Leeuwen JP
J Steroid Biochem Mol Biol; 1995 Dec; 55(3-4):337-46. PubMed ID: 8541230
[TBL] [Abstract][Full Text] [Related]
16. Alendronate interacts with the inhibitory effect of 1,25(OH)2D3 on parathyroid hormone-related protein expression in human osteoblastic cells.
Gómez-García L; Esbrit P; Carreño L; Sabando P; García-Flores M; Martinez ME
J Bone Miner Res; 2003 Jan; 18(1):78-87. PubMed ID: 12510808
[TBL] [Abstract][Full Text] [Related]
17. Temporal changes in tissue 1α,25-dihydroxyvitamin D3, vitamin D receptor target genes, and calcium and PTH levels after 1,25(OH)2D3 treatment in mice.
Chow EC; Quach HP; Vieth R; Pang KS
Am J Physiol Endocrinol Metab; 2013 May; 304(9):E977-89. PubMed ID: 23482451
[TBL] [Abstract][Full Text] [Related]
18. Effect of combination treatment with a vitamin D analog (OCT) and a bisphosphonate (AHPrBP) in a nude mouse model of cancer-associated hypercalcemia.
Endo K; Katsumata K; Iguchi H; Kubodera N; Teramoto T; Ikeda K; Fujita T; Ogata E
J Bone Miner Res; 1998 Sep; 13(9):1378-83. PubMed ID: 9738509
[TBL] [Abstract][Full Text] [Related]
19. The Vitamin D Receptor in Osteoblast-Lineage Cells Is Essential for the Proresorptive Activity of 1α,25(OH)2D3 In Vivo.
Mori T; Horibe K; Koide M; Uehara S; Yamamoto Y; Kato S; Yasuda H; Takahashi N; Udagawa N; Nakamichi Y
Endocrinology; 2020 Nov; 161(11):. PubMed ID: 32987399
[TBL] [Abstract][Full Text] [Related]
20. Regulation of gene Expression by 1alpha,25-dihydroxyvitamin D3 and Its analog EB1089 under growth-inhibitory conditions in squamous carcinoma Cells.
Akutsu N; Lin R; Bastien Y; Bestawros A; Enepekides DJ; Black MJ; White JH
Mol Endocrinol; 2001 Jul; 15(7):1127-39. PubMed ID: 11435613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
